Product Launch
August 08 2003 - 9:31AM
UK Regulatory
BW20030808002008 20030808T123132Z UTC
( BW)(IVAX-CORPORATION)(IVX) Product Launch
Business Editors
UK REGULATORY NEWS
MIAMI--(BUSINESS WIRE)--Aug. 8, 2003--
IVAX Launches Cefuroxime Axetil Tablets
IVAX Corporation (AMEX:IVX) (LSE:IVX.L) announced today that its
wholly owned subsidiary, IVAX Pharmaceuticals, Inc., is distributing
cefuroxime axetil tablets in 250 mg and 500 mg dosage strengths.
Cefuroxime axetil is the generic equivalent of Ceftin(R), which is
marketed by GlaxoSmithKline, and is an orally-administered antibiotic
used to treat patients with mild to moderate infections. The U.S.
sales of Ceftin and cefuroxime axetil tablets in 250 and 500 mg
strength were approximately $239 million for the past twelve months,
ending in March, 31, 2003.
IVAX Corporation, headquartered in Miami, Florida, discovers,
develops, manufactures, and markets branded and brand equivalent
(generic) pharmaceuticals and veterinary products in the U.S. and
internationally.
Copies of this and other news releases may be obtained free of charge
from IVAX' website at http://www.ivax.com.
Short Name: IVAX Corporation
Category Code: PRL
Sequence Number: 00008204
Time of Receipt (offset from UTC): 20030807T194151+0100
--30--GAA/mi* DB/ny
CONTACT: IVAX Corporation, Miami
David Malina, 305/575-6043
KEYWORD: FLORIDA UNITED KINGDOM INTERNATIONAL EUROPE
INDUSTRY KEYWORD: PHARMACEUTICAL PRODUCT
SOURCE: IVAX Corporation
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: http://www.businesswire.com